ACM
AVTX icon

ADAR1 Capital Management’s Avalo Therapeutics AVTX Stock Holding History

ADAR1 Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,393
Closed -$412K – 273
2025
Q3 		$412K Sell
32,393
-72,337
-69% -$622K 0.04% 148
2025
Q2 		$523K Buy
104,730
+94,730
+947% +$442K 0.08% 116
2025
Q1 		$80.1K Buy
+10,000
New +$75.8K 0.01% 170
2024
Q2 		– Sell
-6,000
Closed -$131K – 274
2024
Q1 		$131K Buy
+6,000
New +$32.3K 0.03% 137

Other funds holding AVTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ADAR1 Capital Management's AVTX Position: Q4 2025 in Review

ADAR1 Capital Management sold out of Avalo Therapeutics (AVTX) in Q4 2025, closing a stake of 32,393 shares — an estimated $412K sold.

ADAR1 Capital Management first reported a position in AVTX in Q1 2024 and held it in 4 quarters. The position peaked at $523K in Q2 2025. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

  • ADAR1 Capital Management reported no remaining Avalo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 32,393 Avalo Therapeutics shares in Q4 2025, an estimated $412K.
  • ADAR1 Capital Management first reported a position in Avalo Therapeutics in Q1 2024 and held it in 4 quarters.
  • ADAR1 Capital Management's Avalo Therapeutics position peaked at $523K in Q2 2025.
  • 84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on ADAR1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.